SERUM LDH AS PROGNOSTIC MARKER IN BREAST CARCINOMA PATIENTS

Dr Shilpa Patankar; Dr Sunayana Chatterjee; Dr Mrunal Ketkar

Volume : IX, Issue : VI, June - 2020

SERUM LDH AS PROGNOSTIC MARKER IN BREAST CARCINOMA PATIENTS

Dr Shilpa Patankar, Dr Sunayana Chatterjee, Dr Mrunal Ketkar

Abstract :

Breast cancer is the second leading cause of cancer related deaths in women and is the most common cancer in females, accounting for 23% of all cancer cases.So, early detection of carcinoma is necessary.For early detection of carcinoma, a number of biochemical markers have been studied to evaluate the malignancy–ferritin, gamma glutamyl transferase, carcino–emyonic antigen, sodium dismutase,alkaline phosphatase, glutathione, cholinesterase–but, none of them are ideal and are very expensive for regular follow up.LDH ia the simplest and cheapest to measure. LDH is a 140kDa tetramer molecule that exists in 5 major iso–enzymes, numbered LDH1–LDH5.These iso–enzymes are formed by the association of 2 different types of 35kDa subunits–M (muscle) and H (heart), encoded by LDH–A and LDH–B genes respectively. A rapid increase in the number of malignant cells, modulates the LDH level in cytoplasmic compartments of cells, due to upregulation in its gene.This increased LDH level is helpful for fulfillment of metabolic requirement and anaerobic glycolysis in these malignant cells.The value of LDH was found to be specific in patients with east malignancy and also corresponds with TNM staging. Here, in this study an attempt has been made to check serum LDH as a marker for prognosis of east cancer.